Growth Factor and Stem Cell Transplant Candidacy in MDS
Considerations for growth factor and stem cell transplant for patients with MDS is discussed.
Examining Treatment Algorithms for MDS
Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome.
Interview with Scott M. Klares, MD, FCCP: Pulmonologist's Advisory Role in COPD Management
Adverse Events & Existing Treatment Options for Dry Eye Disease
Adverse reactions and challenges with patient adherence to therapy are explored by dry eye disease experts.
Overview of Dry Eye Disease (DED) Causes and Treatments
Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD; explore the current treatment landscape of dry eye disease.
Collaborative Strategies in Hemophilia A Care Cost Management
Russell P. Gollard, MD, FACP, explores effective collaboration among health care professionals, administrators, and specialty pharmacies in managing rare diseases like hemophilia A.
Financial Barriers Impeding Optimal Heart Failure Treatment
Financial considerations associated with heart failure management are dissected.
Treatment Optimization Challenges Associated With Heart Failure
Barriers to optimal heart failure treatment are broken down by the expert panelists.
Harnessing Indication-Specific Data on Biosimilars
Professionals explore the importance of indication-specific data in gastroenterology.
An Overview of Biosimilar Extrapolation During FDA Approval
Specialists define and discuss extrapolation, along with the importance of strong data in specific disease states.
ANNEXA-I Study Overview
A medical expert discusses the findings of a randomized trial investigating the use of andexanet alfa versus usual care in patients with acute intracerebral hemorrhage (ICH) and recent direct oral anticoagulant (DOAC) use.
Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape
Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023.
Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023
An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.
Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers
Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023.
Economic Implications of MDS Management
Financial considerations in MDS treatment are discussed.
MDS-Related Complications Impacting Patient Quality of Life
Key opinion leaders discuss how patient quality of life is impacted by MDS treatment-associated challenges.
Navigating HCC Treatment-Related Toxicities
Toxicity management in HCC treatment is discussed by medical experts.
Key Toxicity Profiles in the Treatment of HCC
Dr Haumschild leads a discussion surrounding toxicity profiles specifically related to HCC.
Community Engagement and Long-Term Commitment: Fostering Trust and Collaboration in Clinical Trials for Ophthalmology
Joseph M. Coney, MD, FACS, discusses the crucial role of ongoing community support and active engagement in boosting clinical trial recruitment and emphasizes the importance of establishing trust and increasing visibility to enhance patient confidence in the process.
Strategies for Treating Preserved Ejection Fraction (HFpEF)
A key opinion leader provides insight into key HFpEF treatment strategies.
Navigating the Patient Journey Through Heart Failure Diagnosis
Medical experts discuss strategies to connect with patients to alleviate concerns potentially associated with converting heart failure therapies.
Evolution of Auto-Substitution in Biosimilar Landscape
Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.
Defining Interchangeability and Switching in Biologics
Medical experts discuss interchangeability designation requirements for biosimilars.
DOAC Usage and Rapid Access to Reversal Agents
Stuart J Connolly, MD, FRCPC, discusses updated strategies for managing intracerebral hemorrhage, emphasizing the significance of timely diagnosis to improve hemostatic efficacy.
Maximizing Health Care Resource Utilization in HCC
Richard Kim, MD, offers perspective regarding optimal use of health care resources in the management of HCC.
The Decision-Making Process Behind Elective Gastroscopy (EGD) in the Treatment of HCC.
The decision to perform an EGD is evaluated between academic and community health care perspectives.
Distinguishing Between Different MDS Subtypes
An expert perspective on the variety of MDS subtypes is provided.
Myelodysplastic Syndrome (MDS) Overview
Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state.
Innovations Needed and Future Directions in Treatment of NSCLC
Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.
PAPILLON Trial Insights: ESMO 2023
Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.
